Close

Novosound signs deal with Nasdaq-listed PAVmed Inc. to advance intravascular imaging technology

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Medtech Startup Raises $35M in Pulsed Field Ablation

Field Medical by Steven Mickelsen has gone on to...

Embedding Precious Metal Materials in Medical Devices

Applying radiopaque materials within the parts of medical devices...

NHS to Come Up with AI-Enabled Early Warning Systems

The National Health System – NHS has gone on...

Enhancing Robotic Surgery Precision: Millisecond Challenge

In the high-stakes world of surgical robotics, every millisecond...

Ultrasound sensor specialist Novosound has signed a commercial partnership agreement with PAVmed Inc., the Nasdaq-listed diversified medical technology company, to develop technology aimed at advancing intravascular imaging. The PAVmed agreement furthers Novosound’s move into healthcare, and its regional expansion into North America.

Dave Hughes, CEO and Co-Founder of Novosound, said: “PAVmed has a strong track record in delivering commercial stage medical technology across medical devices, diagnostics, and digital health – the group is the ideal partner for Novosound as we increasingly gain traction in the international healthcare sector.”

Lishan Aklog, M.D., Chairman and Chief Executive Officer of PAVmed, said: “We believe Novosound’s proprietary ultrasound technology has the potential to be a once-in-a-generation breakthrough in medical imaging. We are excited to partner with Novosound with the goal of revolutionising the global intravascular imaging market.”

Novosound recently secured its latest investment, a £3.7 million round led by Par Equity, supported by Foresight Group (via the Foresight Williams Technology EIS Fund), Kelvin Capital, and Scottish Enterprise.

Paul Munn, Partner, Par Equity, said: “Novosound has developed best-of-class remote sensor technology that is applicable across multiple sectors, the company continues to rack up international business wins including most recently with PAVmed, and Par is pleased to continue to support Dave and his team in the months and years ahead.”

Novosound’s patented thin-film manufacturing process, which eliminates conventional limitations in ultrasound sensors including the high cost of high-resolution imaging, also underpins the company’s pioneering non-destructive testing (NDT) products – the Kelpie, Belenus, and Nebula.

The company has announced a series of international contract wins over the last twelve months, including with aerospace groups BAE Systems and GE Aviation, and Israeli-based digital health company dSound.

 

Latest stories

Related stories

Medtech Startup Raises $35M in Pulsed Field Ablation

Field Medical by Steven Mickelsen has gone on to...

Embedding Precious Metal Materials in Medical Devices

Applying radiopaque materials within the parts of medical devices...

NHS to Come Up with AI-Enabled Early Warning Systems

The National Health System – NHS has gone on...

Enhancing Robotic Surgery Precision: Millisecond Challenge

In the high-stakes world of surgical robotics, every millisecond...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back